ArticleDiabetes, obesity & metabolism2026
Literature-informed ensemble machine learning for three-year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Feature Importance Bias and Competing Risks: Methodological Concerns in Ensemble Models for Diabetic Kidney Disease.Diabetes, obesity & metabolism · 2026Article
- Literature-informed ensemble machine learning for three-year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model.Diabetes, obesity & metabolism · 2026Article
- Developing and validating a clinlabomics-based machine-learning model for early detection of occult diabetic kidney disease: implications for primary care screening.Frontiers in endocrinology · 2026Article
- From explainability to clinical actionability: translating artificial intelligence models into decision support for endocrine disease management.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetic kidney disease (DKD) and diabetic nephropathy (DN) affect around 40% of diabetic patients but lack accurate risk prediction tools that include social determinants and demographic complexity. We developed and validated an ensemble machine learning model for three-year DKD/DN risk prediction with deployment readiness.
methodsWe analysed 18 742 eligible adult type 2 diabetic patients from Prince Sultan Military Medical City (PSMMC) registry between 2019 and 2024 in Riyadh, Saudi Arabia. Using temporal patient-level splitting, we developed a stacked ensemble model (LightGBM + CoxBoost) with several features including multiple literature-informed imputed variables including family history, non-steroidal anti-inflammatory drug (NSAID) use, socioeconomic deprivation, diabetic retinopathy severity, and antihypertensive medications, imputed via Bayesian multiple imputation by chained equations (MICE) with external study priors. Primary outcome was incident/progressive DKD/DN within 3 years' timeframe. We assessed discrimination, calibration, model utilisation, and algorithmic fairness.
resultsThe final model achieved excellent discrimination (receiver operating characteristic [AUROC] of 0.852, 95% CI 0.847-0.857) and near-perfect calibration (slope 0.98, intercept -0.012) on multi-trial validation. Decision curve evaluation demonstrated superior net benefit (+22 events prevented per 1000 patients at 10% threshold) compared to treat-all strategies. Bootstrap validation showed minimal optimism in discrimination (C-statistic optimism = 0.005). No algorithmic bias was detected across demographic subgroups (maximum |Δ-AUROC| = 0.010). Prior sensitivity analysis confirmed validity and significance (AUROC variation ≤0.008). The model was engineered and deployed as an interactive web-based application (https://nephrarisk.streamlit.app/).
conclusionsOur developed and demonstrated model provided accurate and well-fair DKD/DN risk prediction with excellent calibration, allowing for better decision making with deployment as a web-based research tool and framework for future prospective clinical validation. Further validation and testing are warranted from different centres and healthcare systems to increase confidence and dissemination of our model findings for better utilisation purposes in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.